Latest United Kingdom News

4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.

Harvey Norman Holdings reported a 10.9% rise in profit before tax excluding one-off adjustments, driven by international retail growth and a robust property portfolio. The company declared a fully franked 13 cent final dividend, maintaining a strong balance sheet with conservative gearing.

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

RocketBoots reported a 9.7% revenue rise to A$724,815 but deepened its net loss to A$6.6 million, driven by heavy investment ahead of a major contract rollout and international growth.

Janison Education Group has landed a landmark subcontract with NFER to deliver Scotland's national standardised assessments, marking its first UK government contract and a strategic expansion beyond ANZ.

Suncorp Group has updated its dividend details for the half-year ending June 2026, declaring a fully franked total dividend of 62 cents per share payable in Australian or New Zealand dollars with a reinvestment plan available.

Viva Leisure posted a 12.2% revenue increase to $237.1 million and a 144.5% jump in net profit after tax for FY2026, declaring its first fully franked dividend and launching Meridium Global as a standalone payments and technology business.

Cann Group reported its second-ever quarterly operating cash inflow of $0.24 million in Q4 FY2026, edging closer to cash flow break-even. The company expanded exports to the UK and Germany, launched new products, and completed a leadership transition while redeeming convertible notes and securing additional credit.

BLS Pharmaceuticals capped FY2026 with record quarterly revenue and operating cash flow, driven by international expansion and new supply agreements across regulated markets.

OncoSil Medical has gained Saudi FDA approval for its OncoSil™ device, enabling full reimbursement and commercial access in Saudi Arabia, the Middle East's largest healthcare market.

Excite Technology Services has raised $3.26 million through a share placement priced at 0.6 cents each, accompanied by free-attaching options pending shareholder approval. The Managing Director will convert $500,000 of debt into equity on matching terms.

Telix Pharmaceuticals has gained FDA alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, setting the stage for U.S. enrolment pending regulatory approval.